Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2023 - 2026)

Gyre Therapeutics has reported Income from Non-Controlling Interests over the past 3 years, most recently at $357000.0 for Q4 2025.

  • Quarterly Income from Non-Controlling Interests fell 46.56% to $357000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, down 16.51% year-over-year, with the annual reading at $4.9 million for FY2025, 16.51% down from the prior year.
  • Income from Non-Controlling Interests was $357000.0 for Q4 2025 at Gyre Therapeutics, down from $2.3 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $3.5 million in Q3 2023 and troughed at $29000.0 in Q4 2023.
  • The 3-year median for Income from Non-Controlling Interests is $1.4 million (2024), against an average of $1.5 million.
  • Year-over-year, Income from Non-Controlling Interests soared 2203.45% in 2024 and then crashed 56.89% in 2025.
  • A 3-year view of Income from Non-Controlling Interests shows it stood at $29000.0 in 2023, then soared by 2203.45% to $668000.0 in 2024, then tumbled by 46.56% to $357000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Income from Non-Controlling Interests are $357000.0 (Q4 2025), $2.3 million (Q3 2025), and $1.1 million (Q2 2025).